Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Risk Reduction
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Chronic Kidney Disease
100%
Incident Heart Failure
100%
Diabetes Analysis
100%
Finerenone
100%
FIGARO
100%
First Hospitalization
70%
Cardiovascular Mortality
40%
Heart Failure
40%
History of Heart Failure
40%
Heart Failure Outcomes
40%
Hazard Ratio
30%
Placebo
30%
Hospitalization
30%
New-onset Heart Failure
30%
Low Risk
20%
Estimated Glomerular Filtration Rate
20%
Albumin-to-creatinine Ratio
20%
Diabetic Kidney Disease
20%
Rate Ratio
10%
Cardiovascular Outcomes
10%
Type 2 Diabetic Patients
10%
Treatment Group
10%
Low Dose Rate
10%
Clinically Significant
10%
Cardiovascular Morbidity
10%
Treatment-related Adverse Events
10%
Kidney Disease
10%
Kidney Failure
10%
Disease Progression
10%
Symptomatic Heart Failure
10%
Mineralocorticoid Receptor Antagonists
10%
Heart Failure with Preserved Ejection Fraction (HFpEF)
10%
Unique Identifier
10%
Event Outcomes
10%
Recurrent Hospitalization
10%
Failure Progression
10%
FIDELIO-DKD
10%
Failure History
10%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Non Insulin Dependent Diabetes Mellitus
100%
Chronic Kidney Failure
100%
Finerenone
100%
Placebo
18%
Creatinine
12%
Diabetic Nephropathy
12%
Adverse Event
6%
Cardiovascular Mortality
6%
Kidney Disease
6%
Disease Exacerbation
6%
Kidney Failure
6%
Mineralocorticoid Antagonist
6%
Heart Failure with Reduced Ejection Fraction
6%